Why the study?
What is the clinical and economic burden associated with new cardiovascular events among patients with hyperlipidemia?
What is the clinical and economic burden associated with new cardiovascular events among patients with hyperlipidemia?
New cardiovascular events in hyperlipidemic patients are associated with significantly increased healthcare utilization and costs that persist for at least 3 years.
New CVEs drive sustained higher costs in hyperlipidemia; leaves open whether prevention reduces long-term utilization.
Among hyperlipidemic patients with new CVE, healthcare utilization and costs incurred were significantly higher than for those without CVE during the acute phase, and remained higher up to 3 years post-event, across all risk cohorts.
No takes yet. Share an insight, caveat, or question.
Fox et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: